Authors:
Auvinen, A
Vornanen, T
Tammela, TLJ
Ala-Opas, M
Leppilahti, M
Salminen, P
Hakama, M
Citation: A. Auvinen et al., A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics, BJU INT, 88(7), 2001, pp. 708-715
Authors:
Sudah, M
Vanninen, R
Partanen, K
Heino, A
Vainio, P
Ala-Opas, M
Citation: M. Sudah et al., MR urography in evaluation of acute flank pain: T2-weighted sequences and gadolinium-enhanced three-dimensional FLASH compared with urography, AM J ROENTG, 176(1), 2001, pp. 105-112
Authors:
Aaltomaa, S
Lipponen, P
Ala-Opas, M
Kosma, VM
Citation: S. Aaltomaa et al., Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer, EUR UROL, 39(2), 2001, pp. 138-144
Authors:
Gronlund-Pakkanen, S
Pakkanen, TM
Koski, E
Talja, M
Ala-Opas, M
Alhava, E
Citation: S. Gronlund-pakkanen et al., Effect of photodynamic therapy on urinary bladder function: an experimental study with rats, UROL RES, 29(3), 2001, pp. 205-209
Citation: K. Tuhkanen et al., Two-year follow-up results of a prospective randomized trial comparing hybrid laser prostatectomy with TURP in the treatment of big benign prostates, SC J UROL N, 35(3), 2001, pp. 200-204
Citation: S. Aaltomaa et M. Ala-opas, The effect of transurethral needle ablation on symptoms of chronic pelvic pain syndrome - A pilot study, SC J UROL N, 35(2), 2001, pp. 127-131
Authors:
Gronlund-Pakkanen, S
Pakkanen, TM
Talja, M
Kosma, VM
Ala-Opas, M
Alhava, E
Citation: S. Gronlund-pakkanen et al., The morphological changes in rat bladder after photodynamic therapy with 5-aminolaevulinic acid-induced protoporphyrin IX, BJU INT, 86(1), 2000, pp. 126-132
Authors:
Aaltomaa, S
Lipponen, P
Viitanen, J
Kankkunen, JP
Ala-Opas, M
Kosma, VM
Citation: S. Aaltomaa et al., Prognostic value of CD44 standard, variant isoforms 3 and 6 and alpha-catenin expression in local prostate cancer treated by radical prostatectomy, EUR UROL, 38(5), 2000, pp. 555-562
Authors:
Lipponen, P
Aaltomaa, S
Kellokoski, J
Ala-Opas, M
Kosma, VM
Citation: P. Lipponen et al., Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation, EUR UROL, 37(5), 2000, pp. 573-578
Authors:
Liukkonen, T
Lipponen, P
Raitanen, M
Kaasinen, E
Ala-Opas, M
Rajala, P
Kosma, VM
Citation: T. Liukkonen et al., Evaluation of p21(WAF1/CIP1) and cyclin D-1 expression in the progression of superficial bladder cancer, UROL RES, 28(5), 2000, pp. 285-292
Authors:
Lumiaho, J
Heino, A
Pietilainen, T
Ala-Opas, M
Talja, M
Valimaa, T
Tormala, P
Citation: J. Lumiaho et al., The morphological, in situ effects of a self-reinforced bioabsorbable polylactide (SR-PLA 96) ureteric stent; An experimental study, J UROL, 164(4), 2000, pp. 1360-1363
Authors:
Lumiaho, J
Heino, A
Tunninen, V
Ala-Opas, M
Talja, M
Valimaa, T
Tormala, P
Citation: J. Lumiaho et al., New bioabsorbable polylactide ureteral stent in the treatment of ureteral lesions: An experimental study, J ENDOUROL, 13(2), 1999, pp. 107-112
Citation: K. Tuhkanen et al., Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml - Six-month follow-up with complex urodynamic assessment, SC J UROL N, 33(1), 1999, pp. 31-34
Authors:
Aaltomaa, S
Lipponen, P
Ala-Opas, M
Eskelinen, M
Kosma, VM
Citation: S. Aaltomaa et al., alpha-Catenin expression has prognostic value in local and locally advanced prostate cancer, BR J CANC, 80(3-4), 1999, pp. 477-482
Authors:
Aaltomaa, S
Lipponen, P
Ala-Opas, M
Eskelinen, M
Syrjanen, K
Kosma, VM
Citation: S. Aaltomaa et al., Expression of cyclins A and D and p21((waf1/cip1)) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival, BR J CANC, 80(12), 1999, pp. 2001-2007